Mymd Pharmaceuticals (QCLS) Financials

Mymd Pharmaceuticals logo
$0.31 -0.03 (-8.29%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$0.31 0.00 (-0.10%)
As of 11/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Mymd Pharmaceuticals

Annual Income Statements for Mymd Pharmaceuticals

This table shows Mymd Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-9.51 -3.30 -7.37 -10 -3.89 -9.49 -30 -15 -8.22 -27 -15
Consolidated Net Income / (Loss)
-9.31 -3.30 -7.37 -11 -3.89 -9.49 -30 -15 -4.00 -23 -12
Net Income / (Loss) Continuing Operations
-9.51 -3.30 -7.37 -10 -3.38 -9.49 -30 -15 -4.00 -23 -12
Total Pre-Tax Income
-9.58 -3.30 -7.37 -11 -3.38 -9.49 -30 -15 -4.00 -23 -12
Total Operating Income
-9.68 -3.33 -6.61 -10 -3.47 -9.49 -29 -15 -17 -10 -9.85
Total Gross Profit
1.16 1.88 0.95 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
2.12 2.96 3.35 1.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue
2.12 2.96 3.35 1.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.95 1.08 2.41 1.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue
0.95 1.08 2.41 1.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
11 5.21 7.56 10 3.47 9.49 29 15 17 10 9.85
Selling, General & Admin Expense
4.03 3.01 4.08 5.67 3.37 2.95 6.42 5.52 5.44 4.16 3.74
Research & Development Expense
1.41 1.19 1.26 1.06 0.00 2.47 6.75 9.07 7.87 3.44 3.47
Other Operating Expenses / (Income)
2.16 -1.30 - - - 3.20 16 0.00 0.76 1.51 0.46
Other Special Charges / (Income)
- - 0.00 1.51 0.08 0.86 0.00 0.70 3.05 1.06 2.17
Total Other Income / (Expense), net
-0.10 0.03 -0.76 -0.43 0.09 0.00 -1.08 0.09 13 -13 -1.78
Interest & Investment Income
0.10 0.02 0.01 0.15 0.11 0.00 0.05 0.08 0.46 0.35 0.23
Other Income / (Expense), net
-0.00 0.00 -0.77 -0.94 -0.01 0.00 -1.13 0.00 13 -14 -2.01
Income Tax Expense
-0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared
- - - - - - - 0.00 4.22 3.80 3.36
Basic Earnings per Share
($1.81) ($0.61) ($6.29) ($22.28) ($6.35) - ($0.85) ($11.74) ($5.33) ($1,080.87) ($8.66)
Weighted Average Basic Shares Outstanding
5.14M 5.43M 1.17M 486.95K 612.67K 28.19M 35.02M 1.29M 1.54M 25.13K 1.73M
Diluted Earnings per Share
($1.81) ($0.61) ($6.29) ($22.28) ($6.35) - - ($11.74) ($5.33) ($1,080.87) ($8.66)
Weighted Average Diluted Shares Outstanding
5.14M 5.43M 1.17M 486.95K 612.67K 28.19M 35.02M 1.29M 1.54M 25.13K 1.73M

Quarterly Income Statements for Mymd Pharmaceuticals

This table shows Mymd Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-4.89 -11 -10 -2.68 -3.14 -1.94 -2.77 -3.71 -6.56 -1.53 -6.54
Consolidated Net Income / (Loss)
-2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24 -6.62
Net Income / (Loss) Continuing Operations
-2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24 -6.62
Total Pre-Tax Income
-2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24 -6.62
Total Operating Income
-4.91 -2.78 -3.37 -1.83 -2.19 -2.47 -1.87 -1.79 -3.71 -1.86 -6.79
Total Gross Profit
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Operating Revenue
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Operating Cost of Revenue
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Other Cost of Revenue
- - - 0.00 - 0.00 0.00 - - - 0.00
Total Operating Expenses
4.91 2.78 3.37 1.83 2.19 2.47 1.87 1.79 3.71 1.86 6.79
Selling, General & Admin Expense
1.24 1.07 1.02 1.10 0.97 0.84 0.89 0.97 1.03 1.07 1.00
Research & Development Expense
2.96 1.20 0.40 0.71 1.13 1.55 0.87 0.36 0.70 0.51 0.24
Impairment Charge
- - - - - - 0.00 - - - 3.18
Other Special Charges / (Income)
0.71 0.52 0.44 0.01 0.09 0.08 0.10 0.00 1.99 0.06 2.37
Total Other Income / (Expense), net
2.54 -7.02 -6.20 -0.10 0.12 1.35 0.08 -1.02 -2.18 0.61 0.17
Interest & Investment Income
0.12 0.02 0.02 0.16 0.15 0.06 0.06 0.04 0.07 0.08 0.12
Other Income / (Expense), net
2.43 -7.03 -6.22 -0.27 -0.02 1.28 0.02 -1.06 -2.25 0.53 0.05
Income Tax Expense
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Preferred Stock Dividends Declared
2.53 1.20 0.78 0.75 1.07 0.81 0.98 0.90 0.67 0.29 -0.08
Basic Earnings per Share
($3.17) ($5.14) ($4.54) ($107.62) ($124.79) ($0.36) ($51.10) ($2.50) ($3.79) ($0.19) ($0.79)
Weighted Average Basic Shares Outstanding
1.54M 2.14M 2.28M 24.91K 25.13K 5.35M 54.26K 1.48M 1.73M 8.06M 8.24M
Diluted Earnings per Share
($3.17) ($5.14) ($4.54) ($107.62) ($124.79) ($0.36) ($51.10) ($2.50) ($3.79) ($0.19) ($0.79)
Weighted Average Diluted Shares Outstanding
1.54M 2.14M 2.28M 24.91K 25.13K 5.35M 54.26K 1.48M 1.73M 8.06M 8.24M
Weighted Average Basic & Diluted Shares Outstanding
2.16M 2.31M 2.37M 2.76M 0.00 14.18M 176.62M 4.17M 0.00 7.85M 8.19M

Annual Cash Flow Statements for Mymd Pharmaceuticals

This table details how cash moves in and out of Mymd Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-0.05 -0.33 0.60 0.24 0.96 0.01 0.41 0.19 1.93 -2.51 0.81
Net Cash From Operating Activities
-5.13 -4.17 -5.08 -8.50 -3.07 -4.66 -20 -12 -13 -8.98 -9.07
Net Cash From Continuing Operating Activities
-5.13 -4.17 -4.84 -8.82 -2.06 -4.66 -20 -12 -13 -8.98 -9.07
Net Income / (Loss) Continuing Operations
-9.31 -3.30 -7.37 -11 -2.87 -9.49 -30 -15 -4.00 -23 -12
Consolidated Net Income / (Loss)
-9.31 -3.30 -7.37 -11 -3.38 -9.49 -30 -15 -4.00 -23 -12
Non-Cash Adjustments To Reconcile Net Income
3.03 -0.98 2.71 1.42 0.92 3.04 15 0.70 -9.80 15 1.81
Changes in Operating Assets and Liabilities, net
0.85 -0.21 -0.69 0.68 -0.18 0.57 -5.18 2.23 0.82 -0.92 0.75
Net Cash From Investing Activities
5.08 3.84 -5.01 -0.36 -3.94 0.00 20 6.91 1.85 -6.10 -8.42
Net Cash From Continuing Investing Activities
5.08 3.84 -5.01 -0.36 -3.94 0.00 20 6.91 1.85 -6.10 -8.42
Purchase of Investments
-0.06 -0.04 -7.71 -6.60 -6.70 0.00 -0.01 -4.84 -13 -13 -19
Sale and/or Maturity of Investments
5.31 4.00 2.75 6.31 2.86 0.00 18 12 15 6.75 13
Other Investing Activities, net
0.01 - - - -0.10 - - - - 0.00 -2.01
Net Cash From Financing Activities
0.00 0.00 10 9.11 6.97 4.68 0.07 5.55 13 13 18
Net Cash From Continuing Financing Activities
0.00 0.00 10 9.11 6.97 4.68 0.07 5.55 13 13 18
Repurchase of Preferred Equity
- - - - - - - 0.00 -0.09 -0.07 0.00
Payment of Dividends
- - - - - - - 0.00 -1.45 -1.36 -0.08
Issuance of Preferred Equity
- 0.00 3.68 0.00 - - - 0.00 15 14 6.65
Issuance of Common Equity
- 0.00 5.80 1.95 6.97 1.98 0.00 5.55 - 0.00 12
Other Financing Activities, net
- 0.00 0.98 7.16 0.00 0.00 1.19 - -0.08 0.00 0.00
Cash Interest Paid
- - 0.00 0.00 0.00 0.00 0.27 0.01 0.00 0.00 0.00
Cash Income Taxes Paid
- - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Mymd Pharmaceuticals

This table details how cash moves in and out of Mymd Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents
2.38 -2.46 0.31 0.66 -1.02 -0.10 0.13 6.70 -5.92 0.14 -0.82
Net Cash From Operating Activities
-1.93 -1.76 -2.67 -2.43 -2.12 -2.64 -2.07 -1.16 -3.20 -3.29 -1.82
Net Cash From Continuing Operating Activities
-1.93 -1.76 -2.67 -2.43 -2.12 -2.64 -2.07 -1.16 -3.20 -3.29 -1.82
Net Income / (Loss) Continuing Operations
-2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24 -6.62
Consolidated Net Income / (Loss)
-2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24 -6.62
Non-Cash Adjustments To Reconcile Net Income
-1.72 7.55 6.65 0.39 0.71 -1.20 1.39 -0.24 1.87 -1.02 4.85
Changes in Operating Assets and Liabilities, net
2.15 0.49 0.25 -0.89 -0.77 -0.31 -1.66 1.90 0.83 -1.02 -0.07
Net Cash From Investing Activities
5.93 0.73 -11 3.09 1.10 2.54 2.20 -1.49 -12 2.97 1.04
Net Cash From Continuing Investing Activities
5.93 0.73 -11 3.09 1.10 2.54 2.20 -1.49 -12 2.97 1.04
Purchase of Investments
-0.12 -0.02 -13 -0.16 -0.15 -5.86 -0.06 -0.04 -13 -0.14 -0.07
Sale and/or Maturity of Investments
6.05 0.75 1.50 3.25 1.25 8.40 2.26 0.55 1.44 3.12 1.26
Net Cash From Financing Activities
-1.62 -1.43 14 - 0.00 0.00 - 9.35 8.95 0.45 -0.04
Net Cash From Continuing Financing Activities
-1.62 -1.43 14 - 0.00 0.00 - 9.35 8.95 0.45 -0.04
Issuance of Common Equity
- - - - - 0.00 - - 9.03 0.51 0.01

Annual Balance Sheets for Mymd Pharmaceuticals

This table presents Mymd Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
8.27 5.09 9.34 7.81 11 0.68 25 18 18 21 41
Total Current Assets
6.48 3.19 7.78 6.67 10 0.15 13 5.40 5.82 9.41 17
Cash & Equivalents
0.40 0.07 0.44 0.18 0.52 0.15 0.56 0.75 2.68 0.17 0.99
Short-Term Investments
4.03 0.05 5.01 5.27 9.16 0.00 11 4.09 2.24 8.35 15
Accounts Receivable
0.74 0.66 0.98 0.19 0.00 - - - - - 0.02
Prepaid Expenses
0.19 0.37 0.40 0.44 0.33 0.00 1.11 0.57 0.89 0.89 0.77
Plant, Property, & Equipment, net
0.25 0.26 0.24 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
1.54 1.64 1.33 1.05 0.57 0.53 12 12 12 12 25
Goodwill
- - - - - 0.00 10 10 10 10 10
Intangible Assets
1.47 1.30 1.13 0.24 - - - - - 0.00 14
Other Noncurrent Operating Assets
0.07 0.34 0.20 0.81 0.12 0.53 0.15 0.14 1.55 1.51 0.00
Total Liabilities & Shareholders' Equity
8.27 5.09 9.34 7.81 11 0.68 25 18 18 21 41
Total Liabilities
1.67 1.70 1.79 1.97 1.53 5.93 1.17 2.84 5.09 6.70 16
Total Current Liabilities
1.67 1.70 1.79 1.97 1.53 2.35 1.04 2.77 4.99 6.70 5.53
Accounts Payable
1.67 1.70 1.79 1.97 0.89 1.80 0.99 2.67 3.72 2.90 2.45
Dividends Payable
- - - - - - - 0.00 0.27 2.46 0.37
Other Current Liabilities
- - - - - 0.48 0.05 0.10 1.01 1.34 2.72
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 3.59 0.13 0.08 0.10 0.00 11
Other Noncurrent Operating Liabilities
- - - - 0.00 0.05 0.13 0.08 - 0.00 11
Commitments & Contingencies
- - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
- - - - - - - 0.00 6.50 19 12
Total Equity & Noncontrolling Interests
6.60 3.39 7.55 5.83 9.36 -5.26 24 15 6.27 -3.84 13
Total Preferred & Common Equity
6.60 3.39 7.55 5.83 9.36 -5.26 24 15 12 9.79 22
Preferred Stock
0.00 0.00 1.76 0.00 0.00 0.00 0.14 0.14 -5.95 -13 -8.80
Total Common Equity
6.60 3.39 5.80 5.83 9.36 -5.26 24 15 12 9.65 22
Common Stock
101 101 111 122 129 43 102 108 114 139 166
Retained Earnings
-94 -97 -105 -116 -120 -49 -79 -94 -102 -129 -144

Quarterly Balance Sheets for Mymd Pharmaceuticals

This table presents Mymd Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets
22 14 26 24 19 17 37 38 23
Total Current Assets
9.74 2.46 14 12 6.78 5.15 11 14 12
Cash & Equivalents
0.30 0.23 0.54 1.19 0.07 0.21 6.90 1.13 0.31
Short-Term Investments
8.17 1.51 14 11 5.81 3.61 3.09 12 11
Accounts Receivable
- - - - - - - 0.02 0.02
Prepaid Expenses
1.26 0.73 1.29 1.39 0.90 1.34 1.15 0.71 0.74
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14
Total Noncurrent Assets
12 12 11 11 12 12 26 25 11
Goodwill
10 10 10 10 10 10 10 10 10
Intangible Assets
- - - - - - - 14 0.00
Other Noncurrent Operating Assets
0.09 1.53 0.03 0.02 1.50 1.50 16 - 0.49
Total Liabilities & Shareholders' Equity
22 14 26 24 19 17 37 38 23
Total Liabilities
5.72 4.25 26 6.99 4.94 5.55 16 15 3.79
Total Current Liabilities
5.70 3.97 5.78 6.99 4.94 5.55 6.53 3.69 3.57
Accounts Payable
2.03 3.86 4.62 4.16 2.59 2.68 3.18 1.38 1.34
Dividends Payable
0.20 0.05 0.78 1.50 2.29 2.84 0.09 0.59 0.45
Other Current Liabilities
3.46 0.07 0.06 1.33 0.05 0.03 3.26 1.71 1.78
Total Noncurrent Liabilities
0.02 0.28 20 0.00 0.00 0.00 9.38 11 0.23
Other Noncurrent Operating Liabilities
0.02 0.28 - - - - 9.38 11 0.23
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.61 4.88 0.28 0.28 5.15 6.32 19 12 12
Total Equity & Noncontrolling Interests
16 5.36 0.10 17 8.69 5.28 2.82 12 7.15
Total Preferred & Common Equity
16 9.94 0.10 17 8.69 5.28 14 21 16
Preferred Stock
0.14 -4.43 0.14 0.14 0.14 0.14 -11 -8.80 -8.80
Total Common Equity
15 9.79 -0.05 17 8.55 5.13 14 21 16
Common Stock
112 123 123 143 140 139 152 166 168
Retained Earnings
-97 -113 -123 -126 -131 -134 -138 -146 -152

Annual Metrics And Ratios for Mymd Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Mymd Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
5,144,837.00 5,452,545.00 19,841,104.00 12,474,028.00 12,520,208.00 8,859,868.00 37,639,912.00 39,470,009.00 50,900,715.00 2,755,067.00 4,166,760.00
DEI Adjusted Shares Outstanding
4.00 5.00 17.00 87.00 87.00 1,477.00 12,547.00 13,157.00 16,967.00 27,551.00 4,166,760.00
DEI Earnings Per Adjusted Shares Outstanding
-2,378,464.75 -660,707.60 -433,312.35 -120,600.46 -44,692.52 -6,423.71 -2,382.17 -1,155.08 -484.36 -985.85 -3.60
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-52.23% 39.99% 13.30% -50.35% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-229.02% 67.93% -136.28% -51.37% 68.29% -142.56% -254.31% 47.90% 70.84% -432.17% 50.01%
EBIT Growth
-202.48% 65.66% -121.95% -49.04% 68.30% -172.12% -215.53% 48.96% 70.84% -432.17% 50.01%
NOPAT Growth
-202.18% 65.62% -98.69% -52.11% 65.49% -173.26% -203.64% 46.95% -12.04% 40.61% 3.16%
Net Income Growth
-196.28% 64.52% -122.98% -47.28% 64.16% -144.01% -215.03% 49.15% 73.68% -483.99% 50.22%
EPS Growth
-174.24% 66.30% -122.98% -47.28% 71.50% 0.00% 0.00% 0.00% 73.68% -483.99% 99.20%
Operating Cash Flow Growth
-316.52% 18.69% -21.74% -67.35% 63.84% -51.70% -318.49% 37.13% -5.79% 30.85% -0.99%
Free Cash Flow Firm Growth
-28.79% 11.60% -1.42% -53.38% 69.70% -227.71% -516.49% 73.99% -38.66% 34.77% 1.58%
Invested Capital Growth
-57.22% 50.04% -35.59% -81.98% -216.10% -309.25% 687.99% -21.05% -2.91% 6.67% 7.46%
Revenue Q/Q Growth
-31.62% 6.65% 9.30% -28.36% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-45.98% 48.21% -70.18% 1.33% 46.66% 5.13% -4.62% -3.89% 23.04% 1.11% -46.27%
EBIT Q/Q Growth
-43.31% 45.41% -66.01% 1.40% 46.48% -8.73% -5.77% -3.89% 23.04% 1.11% -46.27%
NOPAT Q/Q Growth
-43.33% 45.34% -48.34% 3.12% 37.33% -8.53% -5.21% -5.34% -6.87% 21.10% -18.33%
Net Income Q/Q Growth
-40.09% 42.89% -65.88% 1.67% 39.12% -2.49% -5.92% -3.44% 25.68% 1.27% -49.13%
EPS Q/Q Growth
-38.17% 42.99% -65.88% 1.67% 43.00% 0.00% 0.00% -3.44% 25.68% 1.27% -11.17%
Operating Cash Flow Q/Q Growth
-55.40% 10.55% -18.30% -16.65% 41.01% -19.06% -22.34% 17.28% 2.37% -2.14% -13.51%
Free Cash Flow Firm Q/Q Growth
3.94% 9.12% -11.99% -2.85% 40.67% -0.82% -13.54% 22.19% -50.28% 15.76% 30.37%
Invested Capital Q/Q Growth
-47.89% -11.15% -42.39% -75.58% -212.92% -265.88% 17.46% -14.20% 27.99% 35.03% -18.48%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
55.05% 63.42% 28.28% 7.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-443.66% -101.62% -211.92% -646.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-457.78% -112.42% -197.15% -604.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-457.85% -112.30% -220.00% -660.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-440.27% -111.57% -219.58% -651.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
97.19% 100.00% 100.00% 100.00% 114.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
98.94% 99.35% 99.81% 98.63% 96.98% 100.00% 99.84% 99.45% 89.78% 98.52% 98.10%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-186.66% -85.65% -172.50% -567.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-150.83% -42.86% -74.28% -497.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
99.67% 19.52% 37.84% 405.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-86.99% -66.13% -134.66% -162.09% -51.20% -463.03% -325.06% -79.27% -29.12% -169.93% -58.95%
Cash Return on Invested Capital (CROIC)
-106.51% -125.68% -129.20% -428.60% 0.00% 0.00% -307.47% -89.39% -142.55% -91.34% -83.95%
Operating Return on Assets (OROA)
-77.71% -49.79% -102.34% -128.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-74.73% -49.47% -102.15% -126.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-86.99% -66.13% -113.06% -140.84% -51.20% -463.03% -322.50% -78.67% -28.39% -135.17% -46.71%
Return on Equity Simple (ROE_SIMPLE)
-141.02% -97.52% -97.53% -185.97% -41.56% 180.48% -126.40% -103.42% -32.34% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.78 -2.33 -4.63 -7.04 -2.43 -6.64 -20 -11 -12 -7.12 -6.89
NOPAT Margin
-320.44% -78.69% -138.00% -422.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-35.83% -42.79% -98.22% -69.82% -19.12% -89.80% -202.49% -46.40% 145.28% -302.99% -44.07%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -191.06% 185.45% -53.82%
Cost of Revenue to Revenue
44.95% 36.58% 71.72% 92.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
190.52% 101.62% 121.69% 340.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
66.52% 40.15% 37.57% 63.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
512.82% 175.84% 225.43% 611.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-9.68 -3.33 -7.38 -11 -3.49 -9.49 -30 -15 -4.46 -24 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.38 -3.01 -7.11 -11 -3.41 -8.28 -29 -15 -4.46 -24 -12
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.94 3.05 0.22 2.26 0.21 0.00 9.03 3.07 0.98 0.30 0.32
Price to Tangible Book Value (P/TBV)
1.21 4.95 0.27 2.36 0.21 0.00 16.32 11.02 6.93 0.00 0.00
Price to Revenue (P/Rev)
2.94 3.48 0.37 7.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.82 3.12 0.00 20.45 0.00 0.00 18.82 4.60 0.94 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.85 3.44 0.00 4.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 -0.69 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 -0.67 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.66 -0.46 -0.51 -0.81 -1.00 -1.55 -0.52 -0.51 -0.40 -0.39 -0.54
Leverage Ratio
1.16 1.34 1.32 1.28 1.23 2.82 1.39 1.10 1.29 1.43 1.59
Compound Leverage Factor
1.15 1.33 1.32 1.26 1.19 2.82 1.38 1.10 1.16 1.41 1.56
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% -218.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% -4.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% -213.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 23.24% 0.00% 0.00% 0.00% 0.61% 0.98% -46.59% -91.60% -35.59%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 50.89% 126.08% 48.20%
Common Equity to Total Capital
100.00% 100.00% 76.76% 100.00% 100.00% 318.14% 99.39% 99.02% 95.71% 65.53% 87.39%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.44 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.42 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.43 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.54 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.52 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.53 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-16.61 -24.41 -16.78 -20.45 -14.70 -145.19 101.37 -0.76 -7.35 -11.68 -5.28
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 16.04% 13.11% 0.00% 0.00% 0.79% 0.75% 2.52% 20.45% 20.77%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.88 1.88 4.36 3.38 6.74 0.06 12.18 1.95 1.17 1.40 3.00
Quick Ratio
3.09 0.46 3.60 2.86 6.33 0.06 11.12 1.75 0.99 1.27 2.86
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.87 -3.42 -3.47 -5.32 -1.61 -5.28 -33 -8.47 -12 -7.66 -7.54
Operating Cash Flow to CapEx
-4,543.87% -3,384.52% -9,320.66% -12,464.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.17 0.44 0.47 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
1.51 4.25 4.10 2.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.93 0.68 1.61 2.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
9.35 11.60 13.57 10.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.59 0.64 1.38 0.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
241.26 85.87 89.12 127.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
390.95 533.84 226.34 181.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
615.60 567.20 264.14 445.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
16.61 52.51 51.32 -136.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
2.18 3.26 2.10 0.38 -0.44 -1.80 11 8.36 8.12 8.66 9.30
Invested Capital Turnover
0.58 1.09 1.25 1.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-2.91 1.09 -1.16 -1.72 -0.82 -1.36 12 -2.23 -0.24 0.54 0.65
Enterprise Value (EV)
1.79 10 -2.44 7.75 -7.72 60 199 38 7.60 -0.55 -5.77
Market Capitalization
6.22 10 1.26 13 1.96 56 212 45 12 2.89 6.90
Book Value per Share
$1.28 $0.62 $0.58 $0.47 $0.75 ($0.59) $0.62 $0.37 $0.24 $3.50 $5.19
Tangible Book Value per Share
$1.00 $0.38 $0.47 $0.45 $0.75 ($0.59) $0.35 $0.10 $0.03 ($0.31) ($0.71)
Total Capital
6.60 3.39 7.55 5.83 9.36 -1.65 24 15 13 15 25
Total Debt
0.00 0.00 0.00 0.00 0.00 3.60 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 3.53 0.00 0.00 0.00 0.00 0.00
Net Debt
-4.43 -0.12 -5.45 -5.45 -9.68 3.46 -13 -6.34 -4.92 -8.52 -16
Capital Expenditures (CapEx)
0.11 0.12 0.05 0.07 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.39 1.37 0.54 -0.76 -0.90 -2.28 0.07 -2.20 -4.09 -5.81 -4.74
Debt-free Net Working Capital (DFNWC)
4.81 1.49 5.99 4.70 8.78 -2.13 12 2.63 0.83 2.71 11
Net Working Capital (NWC)
4.81 1.49 5.99 4.70 8.78 -2.20 12 2.63 0.83 2.71 11
Net Nonoperating Expense (NNE)
2.53 0.97 2.74 3.81 1.46 2.85 9.72 4.50 -7.99 16 4.73
Net Nonoperating Obligations (NNO)
-4.43 -0.12 -5.45 -5.45 -9.80 3.46 -13 -6.34 -4.66 -6.06 -15
Total Depreciation and Amortization (D&A)
0.30 0.32 0.27 0.24 0.07 1.21 0.61 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
18.21% 46.16% 16.12% -45.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
227.53% 50.31% 178.58% 281.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
227.53% 50.31% 178.58% 281.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($347.52) ($117.12) ($117.12) ($23.76) ($6.35) ($2.49) $0.00 ($11.70) ($5.33) ($1,115.00) ($8.66)
Adjusted Weighted Average Basic Shares Outstanding
28.26K 28.28K 426.95K 520.11K 2.70M 16.65M 38.06M 1.29M 1.54M 24.37K 1.73M
Adjusted Diluted Earnings per Share
($347.52) ($117.12) ($117.12) ($23.76) ($6.35) ($2.49) $0.00 $0.00 ($5.33) ($1,115.00) ($8.66)
Adjusted Weighted Average Diluted Shares Outstanding
28.26K 28.28K 426.95K 520.11K 2.70M 16.65M 38.06M 1.32M 1.54M 24.37K 1.73M
Adjusted Basic & Diluted Earnings per Share
($347.52) ($117.12) ($117.12) ($23.76) ($6.35) ($2.49) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
26.78K 28.28K 49.45K 457.24K 612.67K 7.05M 35.02M 1.32M 2.16M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-6.45 -2.33 -4.63 -5.99 -2.38 -6.04 -20 -10 -9.85 -6.38 -5.37
Normalized NOPAT Margin
-305.01% -78.69% -138.00% -359.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-453.00% -111.57% -219.58% -651.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -36.30% -5.81% -0.67%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -36.30% -5.81% -0.67%

Quarterly Metrics And Ratios for Mymd Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Mymd Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding
50,900,715.00 2,157,632.00 2,307,632.00 2,370,423.00 2,755,067.00 2,755,067.00 14,184,088.00 176,615,658.00 4,166,760.00 4,166,760.00 7,853,429.00
DEI Adjusted Shares Outstanding
16,967.00 21,576.00 23,076.00 23,704.00 27,551.00 27,551.00 141,841.00 1,766,157.00 4,166,760.00 4,166,760.00 7,853,429.00
DEI Earnings Per Adjusted Shares Outstanding
-288.30 -509.91 -448.21 -113.08 -113.82 -70.35 -19.55 -2.10 -1.57 -0.37 -0.83
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
34.98% -538.51% -120.77% -153.62% 10.76% 87.89% 80.66% -36.02% -169.47% -11.47% -263.38%
EBIT Growth
34.98% -538.51% -120.77% -153.62% 10.76% 87.89% 80.66% -36.02% -169.47% -11.47% -263.38%
NOPAT Growth
-28.90% -7.50% 41.72% 66.74% 55.41% 11.23% 44.43% 2.03% -69.69% 24.95% -262.63%
Net Income Growth
36.90% -548.27% -129.52% -147.72% 12.66% 88.52% 81.22% -45.71% -185.57% -10.49% -268.35%
EPS Growth
36.90% -328.33% -40.99% -147.72% 12.66% 88.52% 96.04% 97.68% 96.96% 47.22% 98.45%
Operating Cash Flow Growth
14.04% 55.76% 31.92% 23.02% -9.74% -50.25% 22.60% 52.25% -50.87% -24.48% 11.95%
Free Cash Flow Firm Growth
-631.28% -233.79% -265.91% -205.96% 35.04% 74.33% 51.70% -363.72% -56.50% 31.46% 48.13%
Invested Capital Growth
-2.91% 396.61% 568.99% 1.11% 6.67% 19.94% 56.07% 78.00% 7.46% 10.29% -19.68%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-163.51% -296.03% 2.36% 78.16% -5.69% 46.24% -55.85% -53.60% -109.39% 77.76% -408.06%
EBIT Q/Q Growth
-163.51% -296.03% 2.36% 78.16% -5.69% 46.24% -55.85% -53.60% -109.39% 77.76% -408.06%
NOPAT Q/Q Growth
10.58% 43.27% -21.01% 45.82% -19.90% -12.93% 24.24% 4.48% -107.66% 50.05% -266.04%
Net Income Q/Q Growth
-158.46% -314.63% 2.39% 79.83% -6.99% 45.51% -59.70% -56.52% -109.68% 78.92% -432.38%
EPS Q/Q Growth
-158.46% -62.15% 11.67% 79.83% -6.99% 45.51% 50.00% -1,288.89% -51.60% 94.99% -315.79%
Operating Cash Flow Q/Q Growth
38.77% 9.08% -51.86% 8.94% 12.72% -24.49% 21.77% 43.82% -175.78% -2.71% 44.67%
Free Cash Flow Firm Q/Q Growth
-624.38% -319.25% 20.63% 87.31% -53.80% -65.64% -49.34% -21.88% 48.09% 27.46% -13.03%
Invested Capital Q/Q Growth
27.99% 5.38% -20.35% -5.87% 35.03% 18.48% 3.65% 7.35% -18.48% 21.60% -24.52%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
95.33% 99.81% 99.78% 92.17% 93.30% 94.56% 96.89% 98.74% 98.87% 93.73% 98.22%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-29.12% -101.36% -297.63% -142.68% -169.93% -121.95% -115.40% -40.64% -58.95% -62.58% -108.00%
Cash Return on Invested Capital (CROIC)
-142.55% -275.46% -274.50% -142.60% -91.34% -91.49% -110.89% -121.48% -83.95% -69.70% -81.50%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-28.39% -95.06% -264.21% -137.62% -135.17% -92.86% -48.98% -32.62% -46.71% -48.55% -74.22%
Return on Equity Simple (ROE_SIMPLE)
0.00% -123.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.44 -1.95 -2.36 -1.28 -1.53 -1.73 -1.31 -1.25 -2.60 -1.30 -4.75
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
19.51% -84.51% -220.88% -6.38% -9.93% 22.96% 17.78% -15.18% -30.67% 0.70% -32.38%
Return On Investment Capital (ROIC_SIMPLE)
-54.77% -36.36% -2,411.69% -7.62% 39.92% -19.91% -24.84% -44.46% -20.30% -11.03% -66.51%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-2.48 -9.82 -9.59 -2.09 -2.21 -1.19 -1.85 -2.85 -5.96 -1.33 -6.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.48 -9.82 -9.59 -2.09 -2.21 -1.19 -1.85 -2.85 -5.96 -1.33 -6.74
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.98 0.52 0.00 0.24 0.30 21.91 0.38 0.43 0.32 1.35 2.01
Price to Tangible Book Value (P/TBV)
6.93 0.00 0.00 0.66 0.00 0.00 0.00 1.67 0.00 0.00 5.90
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.94 0.45 0.00 0.00 0.00 18.20 0.43 0.29 0.00 1.59 2.84
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.40 -0.77 -0.55 -0.62 -0.39 -0.22 0.46 -0.54 -0.54 -0.43 -0.38
Leverage Ratio
1.29 1.77 4.34 1.38 1.43 1.38 3.63 1.60 1.59 1.52 1.30
Compound Leverage Factor
1.23 1.77 4.33 1.27 1.33 1.31 3.52 1.58 1.57 1.43 1.28
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
-46.59% -43.28% 37.80% 0.85% -91.60% 1.04% 1.25% -53.29% -35.59% -37.14% -46.13%
Noncontrolling Interests to Total Capital
50.89% 47.66% 74.42% 1.63% 126.08% 37.21% 54.51% 86.79% 48.20% 50.30% 62.53%
Common Equity to Total Capital
95.71% 95.63% -12.22% 97.52% 65.53% 61.74% 44.24% 66.50% 87.39% 86.84% 83.60%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-6.98 -12.55 -7.26 -7.03 -8.37 12.89 -11.10 -5.04 -4.81 -3.98 -4.78
Noncontrolling Interest Sharing Ratio
2.52% 6.21% 11.23% 3.54% 20.45% 23.85% 57.56% 19.71% 20.77% 22.42% 31.28%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.17 0.62 2.48 1.72 1.40 1.37 0.93 1.71 3.00 3.71 3.29
Quick Ratio
0.99 0.44 2.52 1.74 1.27 1.19 0.69 1.53 2.86 3.52 3.09
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.19 -13 -11 -1.35 -2.07 -3.44 -5.13 -6.25 -3.25 -2.35 -2.66
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
8.12 8.55 6.81 6.41 8.66 10 11 11 9.30 11 8.54
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.24 11 8.26 0.07 0.54 1.70 3.82 5.00 0.65 1.06 -2.09
Enterprise Value (EV)
7.60 3.83 -9.95 -7.68 -0.55 187 4.58 3.30 -5.77 18 24
Market Capitalization
12 5.12 4.19 4.03 2.89 187 1.93 6.16 6.90 28 32
Book Value per Share
$0.24 $0.19 ($0.02) $7.02 $3.50 $3.10 $0.36 $0.08 $5.19 $4.94 $2.03
Tangible Book Value per Share
$0.03 ($0.01) ($4.57) $2.59 ($0.31) ($0.71) ($0.38) $0.02 ($0.71) ($0.96) $0.69
Total Capital
13 10 0.38 17 15 14 12 21 25 24 19
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-4.92 -1.74 -15 -12 -8.52 -5.88 -3.81 -10.00 -16 -13 -11
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.09 -3.25 -5.99 -7.10 -5.81 -4.04 -4.21 -5.38 -4.74 -2.96 -2.81
Debt-free Net Working Capital (DFNWC)
0.83 -1.51 8.57 5.04 2.71 1.84 -0.40 4.61 11 10 8.18
Net Working Capital (NWC)
0.83 -1.51 8.57 5.04 2.71 1.84 -0.40 4.61 11 10 8.18
Net Nonoperating Expense (NNE)
-1.07 7.85 7.21 0.65 0.53 -0.61 0.49 1.56 3.29 -0.06 1.86
Net Nonoperating Obligations (NNO)
-4.66 -1.69 6.43 -11 -6.06 -3.59 -0.97 -9.91 -15 -12 -11
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($3.17) ($5.14) ($4.54) ($111.00) ($12,479.00) ($36.00) ($0.18) ($2.50) ($3.79) ($0.19) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding
1.54M 2.14M 2.28M 24.15K 251.00 53.50K 15.70M 1.48M 1.73M 8.06M 8.24M
Adjusted Diluted Earnings per Share
($3.17) ($5.14) ($4.54) ($111.00) ($12,479.00) ($36.00) ($0.18) ($2.50) ($3.79) ($0.19) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding
1.54M 2.31M 2.28M 24.15K 251.00 53.50K 15.70M 1.48M 1.73M 8.06M 8.24M
Adjusted Basic & Diluted Earnings per Share
($3.17) $0.00 $0.00 $0.00 ($12,479.00) $0.00 $0.00 $0.00 ($3.79) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.16M 2.31M 2.37M 27.55K 0.00 141.84K 176.62M 4.17M 0.00 7.85M 8.19M
Normalized Net Operating Profit after Tax (NOPAT)
-2.94 -1.59 -2.05 -1.27 -1.47 -1.67 -1.24 -1.25 -1.21 -1.26 -0.87
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
-36.30% 0.00% -15.50% 0.00% -5.81% 0.00% -0.98% 0.00% -0.67% 0.00% -1.15%
Augmented Payout Ratio
-36.30% 0.00% -15.50% 0.00% -5.81% 0.00% -0.98% 0.00% -0.67% 0.00% -1.15%

Financials Breakdown Chart

Key Financial Trends

Financial overview: The provided statements identify the company as MyMD Pharmaceuticals, Inc. under ticker TNFA, although the request references NASDAQ:QCLS. Investors should verify the correct ticker before relying on this analysis. The data covers quarterly periods from Q3 2023 through Q2 2026, rather than a complete four-year history.

The company remains a development-stage business with no reported operating revenue in any of the supplied income statements. Its financial position is supported primarily by cash, short-term investments and equity financing, while operating activities continue to consume cash.

  • Liquid assets remain substantial: Cash and short-term investments totaled approximately $11.0 million at June 30, 2026, compared with $12.0 million at March 31, 2026 and $10.4 million at June 30, 2025.
  • Current liquidity is relatively strong: Current assets of $11.7 million exceeded current liabilities of $3.6 million at Q2 2026, producing a current ratio of approximately 3.3.
  • Operating cash burn improved sequentially: Cash used in operating activities declined from $3.3 million in Q1 2026 to $1.8 million in Q2 2026. This was also below the $3.2 million used in Q4 2025.
  • Investment income provides modest support: Interest and investment income increased to $120,000 in Q2 2026 from $83,000 in Q1 2026, reflecting the company’s significant investment holdings.
  • Cash management relies heavily on investments: Short-term investments represented nearly all of the company’s liquid resources at Q2 2026, while cash and equivalents fell to just $308,000 from $1.1 million in Q1. This limits immediately available cash despite the larger investment balance.
  • Financing has been an important source of liquidity: The company issued common equity in Q1 and Q2 2026, while prior periods included preferred-equity financing. Continued access to capital markets may be necessary to fund operations.
  • No revenue or gross profit has been reported: Operating revenue has been zero in every period provided, leaving the company dependent on financing, investment income and other non-operating items rather than a commercial operating base.
  • Net losses remain persistent: Q2 2026 net loss was $6.6 million, or $0.79 per share attributable to common shareholders, compared with a $1.2 million net loss in Q1 2026 and a $5.9 million loss in Q4 2025.
  • Operating expenses increased sharply: Q2 2026 operating expenses totaled $6.8 million, including a $3.2 million impairment charge and $2.4 million in other special charges. This was substantially above $1.9 million in Q1 2026.
  • Accumulated losses and equity complexity remain concerns: Retained earnings were negative $152.2 million at Q2 2026. The balance sheet also includes $11.9 million of redeemable noncontrolling interest and negative preferred-stock equity, while the weighted-average share count increased from 1.7 million in Q4 2025 to 8.2 million in Q2 2026, indicating significant capital-structure and dilution risk.

Overall, the statements show a company with adequate near-term current-asset coverage but no operating revenue, continuing losses and recurring cash burn. The improvement in quarterly operating cash flow is encouraging, but Q2’s large impairment and special charges demonstrate that reported results can be volatile. Future shareholder value will likely depend on successful development or commercialization of the company’s programs, along with its ability to raise capital without excessive dilution.

11/19/26 01:28 AM ETAI Generated. May Contain Errors.

Mymd Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mymd Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Mymd Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$11.63 million in 2025, falling from -$9.31 million in 2015. The previous period was -$23.36 million in 2024. See where experts think Mymd Pharmaceuticals is headed by visiting Mymd Pharmaceuticals' forecast page.

Mymd Pharmaceuticals' total operating income in 2025 was -$9.85 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $9.85 million

Over the last 10 years, Mymd Pharmaceuticals' total revenue changed from $2.12 million in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 11 quarters, Mymd Pharmaceuticals' cash and equivalents has ranged from $73.24 thousand in Q1 2025 to $6.90 million in Q3 2025, and is currently $307.61 thousand as of their latest financial filing in Q2 2026.

Mymd Pharmaceuticals had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Mymd Pharmaceuticals' book value per share changed from 1.28 in 2015 to 5.19 in 2025, a change of 304.0%.



Financial statements for NASDAQ:QCLS last updated on 8/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners